Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) - Oppenheimer Holdings decreased their FY2017 earnings per share (EPS) estimates for shares of Pieris Pharmaceuticals in a report released on Thursday. Oppenheimer Holdings analyst H. Singh now anticipates that the biotechnology company will post earnings of ($0.84) per share for the year, down from their prior forecast of ($0.82). Oppenheimer Holdings also issued estimates for Pieris Pharmaceuticals’ Q1 2018 earnings at ($0.23) EPS, Q2 2018 earnings at ($0.22) EPS, Q4 2018 earnings at ($0.21) EPS, FY2018 earnings at ($0.86) EPS, FY2019 earnings at ($0.90) EPS and FY2020 earnings at ($0.88) EPS.
WARNING: “Oppenheimer Holdings Comments on Pieris Pharmaceuticals, Inc.’s FY2017 Earnings (PIRS)” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://stocknewstimes.com/2017/08/21/oppenheimer-holdings-comments-on-pieris-pharmaceuticals-inc-s-fy2017-earnings-pirs.html.
A number of other research firms also recently issued reports on PIRS. HC Wainwright set a $9.00 price objective on Pieris Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 11th. BidaskClub downgraded Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 26th. Rodman & Renshaw assumed coverage on Pieris Pharmaceuticals in a report on Tuesday, May 30th. They issued a “buy” rating and a $9.00 price objective for the company. Finally, TheStreet upgraded Pieris Pharmaceuticals from a “d” rating to a “c-” rating in a report on Wednesday, May 3rd. Five analysts have rated the stock with a buy rating, Pieris Pharmaceuticals has an average rating of “Buy” and a consensus price target of $8.25.
Shares of Pieris Pharmaceuticals (NASDAQ PIRS) opened at 4.87 on Monday. The company’s 50 day moving average is $5.34 and its 200-day moving average is $3.67. Pieris Pharmaceuticals has a 1-year low of $1.30 and a 1-year high of $6.20. The company’s market capitalization is $215.78 million.
In other news, Director James A. Geraghty acquired 10,000 shares of the firm’s stock in a transaction on Thursday, August 17th. The stock was acquired at an average price of $4.82 per share, for a total transaction of $48,200.00. Following the completion of the acquisition, the director now owns 10,000 shares in the company, valued at $48,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Allan Reine acquired 65,000 shares of the firm’s stock in a transaction on Thursday, August 17th. The stock was purchased at an average price of $4.82 per share, with a total value of $313,300.00. Following the acquisition, the insider now owns 45,000 shares of the company’s stock, valued at approximately $216,900. The disclosure for this purchase can be found here. 4.05% of the stock is currently owned by corporate insiders.
Institutional investors have recently modified their holdings of the stock. Creative Planning increased its position in shares of Pieris Pharmaceuticals by 29.6% in the first quarter. Creative Planning now owns 60,000 shares of the biotechnology company’s stock valued at $156,000 after buying an additional 13,700 shares during the last quarter. Sphera Funds Management LTD. increased its position in shares of Pieris Pharmaceuticals by 23.5% in the first quarter. Sphera Funds Management LTD. now owns 1,000,000 shares of the biotechnology company’s stock valued at $2,600,000 after buying an additional 190,000 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Pieris Pharmaceuticals during the first quarter valued at $661,000. Acadian Asset Management LLC bought a new position in shares of Pieris Pharmaceuticals during the second quarter valued at $162,000. Finally, Schwab Charles Investment Management Inc. bought a new position in shares of Pieris Pharmaceuticals during the second quarter valued at $292,000. Hedge funds and other institutional investors own 45.34% of the company’s stock.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
